Vertex Pharmaceuticals, Inc. (VRTX)
538.63
-3.99
(-0.74%)
USD |
NASDAQ |
Nov 13, 16:00
535.92
-2.71
(-0.50%)
After-Hours: 19:59
Vertex Pharmaceuticals Enterprise Value : 137.73B for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 137.73B |
| November 11, 2026 | 138.85B |
| November 10, 2026 | 139.07B |
| November 09, 2026 | 139.82B |
| November 06, 2026 | 138.87B |
| November 05, 2026 | 137.70B |
| November 04, 2026 | 139.36B |
| November 03, 2026 | 134.73B |
| November 02, 2026 | 140.40B |
| October 30, 2026 | 141.85B |
| October 29, 2026 | 137.07B |
| October 28, 2026 | 134.45B |
| October 27, 2026 | 132.26B |
| October 26, 2026 | 131.36B |
| October 23, 2026 | 132.99B |
| October 22, 2026 | 135.84B |
| October 21, 2026 | 133.14B |
| October 20, 2026 | 130.64B |
| October 19, 2026 | 127.42B |
| October 16, 2026 | 126.86B |
| October 15, 2026 | 129.15B |
| October 14, 2026 | 126.55B |
| October 13, 2026 | 123.18B |
| October 12, 2026 | 128.70B |
| October 09, 2026 | 129.48B |
| Date | Value |
|---|---|
| October 08, 2026 | 127.75B |
| October 07, 2026 | 128.36B |
| October 06, 2026 | 127.51B |
| October 05, 2026 | 127.81B |
| October 02, 2026 | 128.13B |
| October 01, 2026 | 128.64B |
| September 30, 2026 | 132.71B |
| September 29, 2026 | 127.56B |
| September 28, 2026 | 127.80B |
| September 25, 2026 | 127.42B |
| September 24, 2026 | 126.46B |
| September 23, 2026 | 124.93B |
| September 22, 2026 | 124.59B |
| September 21, 2026 | 123.50B |
| September 18, 2026 | 122.90B |
| September 17, 2026 | 124.93B |
| September 16, 2026 | 124.15B |
| September 15, 2026 | 124.49B |
| September 14, 2026 | 125.73B |
| September 11, 2026 | 124.70B |
| September 10, 2026 | 124.48B |
| September 09, 2026 | 126.14B |
| September 08, 2026 | 128.11B |
| September 04, 2026 | 132.47B |
| September 03, 2026 | 135.47B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Alnylam Pharmaceuticals, Inc. | 20.38B |
| Gilead Sciences, Inc. | 226.62B |
| Regeneron Pharmaceuticals, Inc. | 91.75B |
| Sionna Therapeutics, Inc. | -61.75M |
| Amgen, Inc. | 293.45B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 653.60M |
| Revenue (Quarterly) | 3.439B |
| Total Expenses (Quarterly) | 2.785B |
| EPS Diluted (Quarterly) | 2.561 |
| Gross Profit Margin (Quarterly) | 84.70% |
| Profit Margin (Quarterly) | 19.01% |
| Earnings Yield | 2.89% |
| Operating Earnings Yield | 3.30% |
| Normalized Earnings Yield | 2.978 |